Implementing active surveillance for low-risk thyroid carcinoma into clinical practice: collaborative recommendations for Latin America
- PMID: 39420909
- PMCID: PMC11192484
- DOI: 10.20945/2359-4292-2023-0371
Implementing active surveillance for low-risk thyroid carcinoma into clinical practice: collaborative recommendations for Latin America
Abstract
The incidence of thyroid cancer is increasing globally, but mortality rates have remained steady. Many patients with thyroid cancer have low-risk, nonmetastatic intrathyroidal tumors smaller than 2 cm. Active surveillance has shown benefits in these patients, but the adoption of this approach remains below standard in Latin America. The purpose of this article is to identify ways to improve the incorporation of active surveillance into clinical practice for patients with low-risk thyroid carcinoma in Latin America, taking into consideration cultural and geographic factors. Current recommendations include three steps involving patient participation. The first step, which consists of the initial clinical examination, has eight factors requiring special attention. Anxiety must be managed while considering individual, disease-related, cognitive, and environmental aspects. Terms like "overdiagnosis", "incidentaloma," and "overtreatment" must be explained to the patient. Implementing precise terminology contributes to adequate disease perception, substantially reducing stress and anxiety. Clarifying the nonprogressive nature of thyroid cancer helps dispel myths surrounding the disease. The second step includes advice about procedures and guidelines for patients who choose active surveillance. Flexible monitoring techniques should be implemented, with regular check-ins scheduled based on patient needs. Reasons for adjusting treatment must be clearly communicated to the patient, and changes in preference regarding active surveillance should be considered in advance. The third step includes assistance during follow-up. Patients must be educated about ultrasound results and receive surgical indications from specialized physicians. The effectiveness of active surveillance can be reinforced by explaining to the patients the dynamics of changes in nodule size using clear and concise visual aids.
Keywords: Thyroid carcinoma; active surveillance; decision making; patient preference; risk; ultrasonography.
Conflict of interest statement
Disclosure: no potential conflict of interest relevant to this article was reported.
Figures
Similar articles
-
Active surveillance of papillary thyroid carcinoma in Latin America: a scoping review.Arch Endocrinol Metab. 2024 Sep 24;68:e230495. doi: 10.20945/2359-4292-2023-0495. eCollection 2024. Arch Endocrinol Metab. 2024. PMID: 39420943 Free PMC article.
-
Terminology Change for Small Low-Risk Papillary Thyroid Cancer As a Response to Overtreatment: Results from Three Australian Community Juries.Thyroid. 2021 Jul;31(7):1067-1075. doi: 10.1089/thy.2020.0694. Epub 2021 Jan 5. Thyroid. 2021. PMID: 33238815
-
Applying Criteria of Active Surveillance to Low-Risk Papillary Thyroid Cancer Over a Decade: How Many Surgeries and Complications Can Be Avoided?Thyroid. 2017 Apr;27(4):518-523. doi: 10.1089/thy.2016.0568. Epub 2017 Feb 22. Thyroid. 2017. PMID: 28125944
-
A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma.Thyroid. 2016 Jan;26(1):144-9. doi: 10.1089/thy.2015.0178. Epub 2015 Nov 5. Thyroid. 2016. PMID: 26414743 Free PMC article.
-
Active Surveillance for Low-Risk Thyroid Cancers: A Review of Current Practice Guidelines.Endocrinol Metab (Seoul). 2024 Feb;39(1):47-60. doi: 10.3803/EnM.2024.1937. Epub 2024 Feb 15. Endocrinol Metab (Seoul). 2024. PMID: 38356210 Free PMC article. Review.
Cited by
-
Global research landscape on active surveillance for papillary thyroid microcarcinoma: a bibliometric analysis.Discov Oncol. 2025 Jun 7;16(1):1026. doi: 10.1007/s12672-025-02789-5. Discov Oncol. 2025. PMID: 40481973 Free PMC article.
-
Multikinase and highly selective kinase inhibitors in the neoadjuvant treatment of patients with thyroid cancer.Explor Target Antitumor Ther. 2025 Feb 13;6:1002291. doi: 10.37349/etat.2025.1002291. eCollection 2025. Explor Target Antitumor Ther. 2025. PMID: 40061140 Free PMC article. Review.
-
2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma.Endocrinol Metab (Seoul). 2025 Jun;40(3):307-341. doi: 10.3803/EnM.2025.2461. Epub 2025 Jun 24. Endocrinol Metab (Seoul). 2025. PMID: 40598902 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical